J&J May Seek Better Deal For Guidant After ICD Recalls Lower Stock Price
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson will likely ask Guidant to lower its acquisition price by roughly $2 bil. after recent ICD recalls pushed Guidant's stock price down approximately 10%
You may also be interested in...
Guidant Files Lawsuit To Force J&J To Complete Acquisition
Guidant filed a civil lawsuit against Johnson & Johnson on Nov. 7 in an effort to force the healthcare giant to complete its proposed $25.4 bil. acquisition
Guidant Files Lawsuit To Force J&J To Complete Acquisition
Guidant filed a civil lawsuit against Johnson & Johnson on Nov. 7 in an effort to force the healthcare giant to complete its proposed $25.4 bil. acquisition
J&J Invests In Stent Manufacturing Capacity; Sales Driven By Cordis
Johnson & Johnson/Cordis plans to upgrade the coating process for its Cypher sirolimus-eluting stent so that it can satisfy more than half of the U.S. drug-eluting stent demand